The latest data on childhood immunisation coverage by Primary Health Networks for the period 1 April 2021 to 31 March 2022 is now available. Immunisation coverage rates in Central and Eastern Sydney PHN have been generally trending upwards across all 3 ages groups. CESPHN’s coverage rates are currently at 95.06% for the 1-year-old age group, 92.61% for the 2-year-old age group, and 92.46% for the 5-year-old age group.
Aboriginal vaccination and cultural awareness training
Aboriginal and Torres Strait Islander peoples have higher rates of some vaccine preventable diseases (VPD) than non-Indigenous persons. For this reason, additional vaccines are available free through the National Immunisation Program.
Cultural awareness training in general practice
Topics: Cultural considerations, Practice considerations, and Closing the Gap
Details:Wednesday 1 June 2022 at 6:00pm to 9:00pm (AEDT)
Many young children have never been exposed to the influenza virus or had an influenza vaccine, and have not developed any immunity, increasing the risk of complications. Children can get very sick from influenza which can cause a serious infection in the lungs and death.
The Children under 5 influenza vaccination campaign is currently promoting messages about the benefits and importance of vaccination to parents through online channels. The Department of Health is undertaking further activity to raise awareness of the importance of influenza vaccination for children under 5 years of age through a targeted mail-out to child care centres.
The COVID-19 vaccine comparison poster provides key differences between each COVID-19 vaccine approved for use in Australia as per the ATAGI guidelines. The poster was updated 19 May to include:
winter booster dose recommendations,
extended dose interval for mRNA vaccine primary course, and
additional foot notes.
Updated ATAGI statement on the Clinical use of Zoster vaccine
The Australian Technical Advisory Group on Immunisation (ATAGI) has released an updated clinical statement on recommendations for the Zostavax vaccine and Shingrix vaccine:
In those aged 50 years and above, Shingrix is preferred over Zostavax for prevention of herpes zoster and its complications, due to its higher efficacy
Shingrix is available in Australia through private prescription only – it is not currently available through the NIP
Zostavax is recommended and funded under the NIP for immunocompetent people aged 70 years of age, with catch-up for those aged 71-79 years until October 2023
Karen Orr Nurse Education Scholarship – 2022 applications now open
Applications for the NCIRS Karen Orr Nurse Immunisation Education Scholarship 2022 are now open. This annual scholarship is offered to a nurse or a midwife to the maximum value of $1,000 in funding for further education by attending a conference or a course to enhance immunisation practice.
Australian citizen or have permanent residency, and
Registered nurse or midwife qualification with current registration with AHPRA, and
Have an appropriate post-registration qualification as an authorised nurse immuniser
COVID-19 live stream update for GPs
COVID-19 vaccinelive stream for GPs – key updates and live Q&A
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…